MRI Assisted Stereotactic Biopsy (MAST) in Patients with Elevated Prostate Cancer Risk and Previous Negative Biopsy

Prostate cancer is the most commonly diagnosed noncutaneous malignancy among men in most western countries [2]. In general, an abnormal serum PSA test and/or a suspicious DRE are the first indicators of prostate cancer and warrant further investigations [3]. A TRUSGB is currently the gold standard for confirming prostate cancer diagnoses. PSA tests are characterized by high sensitivity and low specificity whereas TRUSGB are characterized by their low sensitivity and high specificity [4]. In some cases a TRUSGB will not detect any prostate cancer in a patient with an abnormal DRE and/or rising PSA despite the patient going on to be diagnosed with the disease on repeat biopsy or clinical progression (i.e., false negative).